Results 171 to 180 of about 8,587,641 (307)

Patient-reported outcomes in pancreatic islet transplantation : a systematic review

, 2009
Patient-reported outcomes in pancreatic islet transplantation : a systematic ...
J Shaw (7798793), R Smith (7738349), A Woodcock (13712029), J Speight (7755977), M Reaney (13605682)   +4 more
core  

Intensivist coverage and patient outcomes [PDF]

Journal of Anesthesia, 2019
Won Ho Kim, Hyun-Kyu Yoon, Ho-Jin Lee
openaire   +2 more sources

Comorbidities and Patient Outcomes in Carbapenem-Resistant Gram-negative Bacterial Infections. [PDF]

Open Forum Infect Dis
Jabbour JF, Li Y, Boutzoukas AE, Hanson B, Doi Y, Cober E, Herc E, Komarow L, Munita JM, Stryjewski ME, Arias CA, Paterson DL, Satlin MJ, Fowler VG, Bonomo RA, van Duin D, Antibacterial Resistance Leadership Group, Antibacterial Resistance Leadership Group .   +17 more
europepmc   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes? [PDF]

J Pers Med
Walker PR.
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Impact of ACE Units and Geriatrics Consults on Adherence to the 4Ms and Patient Outcomes. [PDF]

J Am Geriatr Soc
Zeng S, Adler-Milstein J, Thombley R, Harrison JD, Luo M, Boscardin WJ, Ngo S, Rogers S.   +7 more
europepmc   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Improving Patient Outcomes by Bridging Bariatric and Body Contouring Surgery with Comprehensive Prehabilitation. [PDF]

Plast Reconstr Surg Glob Open
Campbell CA, Rubin JP, Weltman A, Allen JD, Angadi SS.   +4 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source